Gain Therapeutics Analyst Ratings
Gain Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/18/2023 | 170.27% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 09/12/2023 | 170.27% | Maxim Group | → $10 | Initiates Coverage On | → Buy |
| 08/31/2023 | 170.27% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 08/14/2023 | 62.16% | Chardan Capital | → $6 | Reiterates | Buy → Buy |
| 08/14/2023 | 170.27% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 06/12/2023 | 170.27% | Oppenheimer | → $10 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 170.27% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/15/2023 | 62.16% | Chardan Capital | $5.75 → $6 | Maintains | Buy |
| 05/01/2023 | 170.27% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 03/27/2023 | 55.41% | Chardan Capital | $4 → $5.75 | Maintains | Buy |
| 12/09/2022 | 8.11% | Chardan Capital | → $4 | Initiates Coverage On | → Buy |
| 11/25/2022 | 170.27% | Oppenheimer | $30 → $10 | Maintains | Outperform |
| 11/14/2022 | 170.27% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 11/14/2022 | 170.27% | BTIG | $30 → $10 | Maintains | Buy |
| 08/19/2022 | 35.14% | B. Riley Securities | $11 → $5 | Downgrades | Buy → Neutral |
| 03/29/2022 | 332.43% | B. Riley Securities | $21 → $16 | Maintains | Buy |
| 03/29/2022 | 224.32% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 11/03/2021 | 467.57% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 04/12/2021 | 710.81% | Oppenheimer | → $30 | Initiates Coverage On | → Outperform |
| 04/12/2021 | 710.81% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/18/2023 | 170.27% | HC Wainwright公司 | →$10 | 重申 | 购买→购买 |
| 09/12/2023 | 170.27% | Maxim集团 | →$10 | 开始承保 | →购买 |
| 2023年08月31日 | 170.27% | HC Wainwright公司 | →$10 | 重申 | 购买→购买 |
| 2023年08月14日 | 62.16% | 查尔丹资本 | →$6 | 重申 | 购买→购买 |
| 2023年08月14日 | 170.27% | HC Wainwright公司 | →$10 | 重申 | 购买→购买 |
| 2023/06/12 | 170.27% | 奥本海默 | →$10 | 重申 | 跑赢→跑赢大盘 |
| 2023年05月15日 | 170.27% | HC Wainwright公司 | →$10 | 重申 | 购买→购买 |
| 2023年05月15日 | 62.16% | 查尔丹资本 | $5.75→$6 | 维护 | 买 |
| 05/01/2023 | 170.27% | HC Wainwright公司 | →$10 | 重申 | →购买 |
| 03/27/2023 | 55.41% | 查尔丹资本 | $4→$5.75 | 维护 | 买 |
| 12/09/2022 | 8.11% | 查尔丹资本 | →$4 | 开始承保 | →购买 |
| 2022年11月25日 | 170.27% | 奥本海默 | $30→$10 | 维护 | 跑赢大盘 |
| 2022年11月14日 | 170.27% | HC Wainwright公司 | $12→$10 | 维护 | 买 |
| 2022年11月14日 | 170.27% | BTIG | $30→$10 | 维护 | 买 |
| 2022年08月19日 | 35.14% | B.莱利证券 | $11→$5 | 评级下调 | 购买→中性 |
| 03/29/2022 | 332.43% | B.莱利证券 | $21→$16 | 维护 | 买 |
| 03/29/2022 | 224.32% | HC Wainwright公司 | →$12 | 开始承保 | →购买 |
| 11/03/2021 | 467.57% | B.莱利证券 | →$21 | 开始承保 | →购买 |
| 04/12/2021 | 710.81% | 奥本海默 | →$30 | 开始承保 | →跑赢大盘 |
| 04/12/2021 | 710.81% | BTIG | →$30 | 开始承保 | →购买 |
What is the target price for Gain Therapeutics (GANX)?
Gain Treeutics(GANX)的目标价格是多少？
The latest price target for Gain Therapeutics (NASDAQ: GANX) was reported by HC Wainwright & Co. on September 18, 2023. The analyst firm set a price target for $10.00 expecting GANX to rise to within 12 months (a possible 170.27% upside). 14 analyst firms have reported ratings in the last year.
Gain治疗公司(纳斯达克代码：GANX)的最新目标价是由HC Wainwright&Co.于2023年9月18日报道的。这家分析公司将目标价定为10美元，预计GANX将在12个月内上涨(可能上涨170.27%)。过去一年，有14家分析公司公布了评级。
What is the most recent analyst rating for Gain Therapeutics (GANX)?
Gain Treeutics(GANX)的最新分析师评级是多少？
The latest analyst rating for Gain Therapeutics (NASDAQ: GANX) was provided by HC Wainwright & Co., and Gain Therapeutics reiterated their buy rating.
Gain治疗公司(纳斯达克代码：GANX)的最新分析师评级是由HC Wainwright&Co.提供的，Gain治疗公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Gain Therapeutics (GANX)?
Gain Treeutics(GANX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Gain Treeutics的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Gain治疗公司的上一次评级是在2023年9月18日提交的，所以你应该预计下一次评级将在2024年9月18日左右提供。
Is the Analyst Rating Gain Therapeutics (GANX) correct?
分析师评级增益治疗公司(GANX)正确吗？
While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a reiterated with a price target of $0.00 to $10.00. The current price Gain Therapeutics (GANX) is trading at is $3.70, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的GANX评级被重申，目标价在0.00美元至10.00美元之间。目前的价格上涨治疗(GANX)的交易价格为3.70美元，这在分析师的预测范围内。